Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DERM NASDAQ:IPHA NASDAQ:MDCX NASDAQ:NVCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDERMJourney Medical$7.20+3.2%$7.03$3.54▼$8.25$162.60M0.891,414 shs93,573 shsIPHAInnate Pharma$1.80+1.7%$1.99$1.29▼$3.51$163.15M0.21186,403 shs4,349 shsMDCXMedicus Pharma$3.03+2.0%$3.88$1.80▼$8.94$40.31MN/A480,196 shs382,012 shsNVCTNuvectis Pharma$8.17-1.3%$8.66$4.44▼$11.80$170.70M-0.25133,694 shs66,402 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDERMJourney Medical+3.15%+0.84%+6.82%+15.20%+21.83%IPHAInnate Pharma+1.69%+4.65%-3.23%-8.63%-16.28%MDCXMedicus Pharma+2.02%-8.46%+13.91%-24.25%+302,999,900.00%NVCTNuvectis Pharma-1.33%+1.11%-5.44%-7.79%+18.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDERMJourney Medical2.4054 of 5 stars3.51.00.00.03.51.70.6IPHAInnate Pharma2.6051 of 5 stars3.83.00.00.02.71.70.0MDCXMedicus Pharma2.1896 of 5 stars3.80.00.00.02.61.70.0NVCTNuvectis Pharma3.3096 of 5 stars3.50.00.00.04.45.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDERMJourney Medical 3.00Buy$9.5031.94% UpsideIPHAInnate Pharma 3.50Strong Buy$11.00511.11% UpsideMDCXMedicus Pharma 3.50Strong Buy$23.50675.58% UpsideNVCTNuvectis Pharma 3.00Buy$17.00108.08% UpsideCurrent Analyst Ratings BreakdownLatest MDCX, IPHA, DERM, and NVCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.007/1/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.006/23/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.006/9/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.005/29/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.005/22/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.005/15/2025DERMJourney MedicalAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/12/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$14.00 ➝ $27.005/8/2025MDCXMedicus PharmaMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $20.004/30/2025NVCTNuvectis PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $15.004/28/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDERMJourney Medical$56.13M2.99N/AN/A$0.91 per share7.91IPHAInnate Pharma$21.77M7.62N/AN/A$0.11 per share16.36MDCXMedicus PharmaN/AN/AN/AN/A$0.29 per shareN/ANVCTNuvectis PharmaN/AN/AN/AN/A$0.50 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDERMJourney Medical-$14.67M-$0.39N/AN/AN/A-14.76%-52.03%-11.28%8/11/2025 (Estimated)IPHAInnate Pharma-$53.53MN/A0.00∞N/AN/AN/AN/A9/17/2025 (Estimated)MDCXMedicus Pharma-$11.16M-$1.16N/AN/AN/AN/A-380.03%-224.22%7/17/2025 (Estimated)NVCTNuvectis Pharma-$19M-$1.13N/AN/AN/AN/A-148.83%-95.60%8/5/2025 (Estimated)Latest MDCX, IPHA, DERM, and NVCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025DERMJourney Medical-$0.06N/AN/AN/A$14.93 millionN/A8/5/2025Q2 2025NVCTNuvectis Pharma-$0.25N/AN/AN/AN/AN/A7/17/2025N/AMDCXMedicus Pharma-$0.39N/AN/AN/AN/AN/A5/14/2025Q1 2025DERMJourney Medical-$0.24-$0.18+$0.06-$0.18$12.05 million$13.14 million5/12/2025Q1 2025MDCXMedicus Pharma-$0.23-$0.42-$0.19-$0.42N/AN/A5/6/2025Q1 2025NVCTNuvectis Pharma-$0.30-$0.27+$0.03-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDERMJourney MedicalN/AN/AN/AN/AN/AIPHAInnate PharmaN/AN/AN/AN/AN/AMDCXMedicus PharmaN/AN/AN/AN/AN/ANVCTNuvectis PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDERMJourney Medical1.071.341.03IPHAInnate Pharma2.522.602.60MDCXMedicus PharmaN/A1.531.53NVCTNuvectis PharmaN/A3.283.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDERMJourney Medical7.25%IPHAInnate Pharma0.16%MDCXMedicus PharmaN/ANVCTNuvectis Pharma96.77%Insider OwnershipCompanyInsider OwnershipDERMJourney Medical15.03%IPHAInnate Pharma31.89%MDCXMedicus Pharma11.20%NVCTNuvectis Pharma30.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDERMJourney Medical9023.30 million19.80 millionN/AIPHAInnate Pharma22092.18 million62.78 millionNot OptionableMDCXMedicus PharmaN/A13.57 million12.05 millionN/ANVCTNuvectis Pharma820.89 million14.52 millionNot OptionableMDCX, IPHA, DERM, and NVCT HeadlinesRecent News About These CompaniesAustin Wealth Management LLC Buys Shares of 40,250 Nuvectis Pharma, Inc. (NASDAQ:NVCT)July 11, 2025 | marketbeat.comIridian Asset Management LLC CT Acquires Shares of 253,972 Nuvectis Pharma, Inc. (NASDAQ:NVCT)July 9, 2025 | marketbeat.comNuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading TherapiesJuly 8, 2025 | finance.yahoo.comNuvectis Pharma (NASDAQ:NVCT) Lowered to "Sell" Rating by Wall Street ZenJune 29, 2025 | marketbeat.comMarlio Charles Mosseri Buys 5,603 Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) StockJune 25, 2025 | insidertrades.comNuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Buys $44,767.97 in StockJune 24, 2025 | marketbeat.comInsider Buying: Nuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Acquires 5,399 Shares of StockJune 21, 2025 | insidertrades.comNuvectis Pharma (NASDAQ:NVCT) Stock Rating Upgraded by Wall Street ZenJune 21, 2025 | marketbeat.comMarlio Charles Mosseri Purchases 5,399 Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) StockJune 20, 2025 | marketbeat.comMarlio Charles Mosseri Purchases 28,043 Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) StockJune 20, 2025 | marketbeat.comInsiders of Nuvectis Pharma, Inc. (NASDAQ:NVCT) must be disappointed as stock fell 10% after recent purchasesJune 18, 2025 | finance.yahoo.comNuvectis Pharma: Still Interesting, But Still Too Risky To Jump InJune 18, 2025 | seekingalpha.comNuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor ConferenceMay 16, 2025 | globenewswire.comNuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Marlio Charles Mosseri Buys 21,167 SharesMay 14, 2025 | insidertrades.comInsider Buying: Nuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Purchases 2,650 Shares of StockMay 10, 2025 | insidertrades.comDoes Nuvectis Pharma (NVCT) Have the Potential to Rally 108.79% as Wall Street Analysts Expect?May 9, 2025 | zacks.comNuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth PlansMay 9, 2025 | finance.yahoo.comNuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights | ...May 6, 2025 | gurufocus.comNuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business HighlightsMay 6, 2025 | gurufocus.comNuvectis Pharma, Inc. Reports Promising Phase 1a Data for NXP900 and Secures $15.5 Million FinancingMay 6, 2025 | quiverquant.comQNuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business HighlightsMay 6, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMDCX, IPHA, DERM, and NVCT Company DescriptionsJourney Medical NASDAQ:DERM$7.20 +0.22 (+3.15%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$7.21 +0.01 (+0.14%) As of 07/16/2025 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.Innate Pharma NASDAQ:IPHA$1.80 +0.03 (+1.69%) Closing price 07/16/2025 03:56 PM EasternExtended Trading$1.81 +0.01 (+0.50%) As of 06:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Medicus Pharma NASDAQ:MDCX$3.03 +0.06 (+2.02%) As of 07/16/2025 04:00 PM EasternMedicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.Nuvectis Pharma NASDAQ:NVCT$8.17 -0.11 (-1.33%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$8.78 +0.61 (+7.47%) As of 06:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Super Micro Stock May Benefit as Cooling Demand Takes Off Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
